Category Archives: LABD

The Price is (always) Right

October 7, 2026 By in $SPSIBI, LABD, LABD-26-18, SNDK, SPBIO, XBI Leave a comment

XBI, Two Days Later

The last post on biotech (LABD) was here, showing a potential trendline.

Next day, within minutes of the open, XBI began a collapse and inverse fund LABD launched higher, finishing up +9.93%, for the day.

From an analysis standpoint, the dramatic action suggests trendline(s) may need to be re-drawn.

We’re going to switch back to the XBI ETF, as it shows the situation more clearly.

Biotech XBI, Daily

There may be other channels in effect, yet to reveal themselves.

Expectation is for continued lower action, it’s up to the market.

The channel could easily be negated if tomorrow is decidedly higher as just happened with SNDK (not advice, not a recommendation).

Stay Tuned

Charts by StockCharts, TC2000

Note:  Posts on this site are for education purposes only.  They provide one firm’s insight on the markets.  Not investment advice.  See additional disclaimer here.

The Danger Point®, trade mark: No. 6,505,279

Decision Point … Biotech

October 5, 2026 By in $SPSIBI, Biotech, LABD, LABD-26-18, SPBIO, XBI, XBI-26-17 1 Comment

At The Edge of Trend

We’re looking at biotech XBI, from the perspective of the 3X Leveraged Inverse Fund, LABD.

During the past four trading days, there have been three contact (verification) points on the right-most trendline.

Note that five trading days ago, LABD had its highest volume day, ever.

Trade Note:

The XBI-26-17 (short) was exited at about break-even, then re-positioned via LABD, as LABD-26-18 (not advice, not a recommendation).

Stay Tuned

Charts by StockCharts, TC2000

Note:  Posts on this site are for education purposes only.  They provide one firm’s insight on the markets.  Not investment advice.  See additional disclaimer here.

The Danger Point®, trade mark: No. 6,505,279

Using Volume Clues

October 1, 2026 By in $SPSIBI, Bert Dohmen, LABD, SPBIO

Leveraged Professionals

Leveraged funds, especially 3X biotech inverse fund LABD, is likely to weed out (bankrupt) an inexperienced participant in due time.

With that said, we have to at least concede there are some deep pocket professionals participating in the same fund during the same hours as our market neophytes.

So, when volume behaves in a way uncharacteristic to the market, something’s up … or about to be up.

Biotech 3X Leveraged Inverse Fund LABD, 1-minute.

The volume spike indicates capitulation or a big player has just moved in.

At the blue ‘arrow’, there are three one-minute bars.

The long entry took place during the second bar (not advice, not a recommendation).

The next chart shows the result.

As Bert Dohmen has said countless times during recent interviews, ‘Nobody looks at volume’.

Stay Tuned

Charts by StockCharts, TC2000

Note:  Posts on this site are for education purposes only.  They provide one firm’s insight on the markets.  Not investment advice.  See additional disclaimer here.

The Danger Point®, trade mark: No. 6,505,279

Biotech at The Edge (again)

September 3, 2026 By in $SPSIBI, ABNB, Biotech, CVNA, KMX, LABD, LABD-26-10, SPBIO, XBI, XBI-26-10 1 Comment

Is The Top, In?

Whether it’s Biotech XBI, Airbnb, CarMax or Carvana, trade set-ups are being worked that take place at the ‘edge of congestion.’

The last update on XBI, was here, August 24th, nine trading days ago.

The short, LABD-26-10 was immediately stopped out at the next session.

The index labored on, grinding in a range while posting a bearish MACD divergence on daily and weekly.

All of which, brings us to now.

The chart shows today’s action could not close above the resistance area posted back in July (not advice, not a recommendation).

There’s been no new daily low (yet).

Stay Tuned

Charts by StockCharts

Note:  Posts on this site are for education purposes only.  They provide one firm’s insight on the markets.  Not investment advice.  See additional disclaimer here.

The Danger Point®, trade mark: No. 6,505,279

Biotech Spotlight

August 24, 2026 By in $SPSIBI, Biotech, Ed Dowd, Greg Hunter, LABD, LABD-26-10, SPBIO, Speck-Effect, Spring-to-Up-Thrust, The Speck, XBI, ZeroHedge 1 Comment

Potential Set-Up

Over the weekend, Greg Hunter released his latest interview with Ed Dowd, link here.

ZeroHedge subsequently picked up that feed, link here.

As is typical with ZeroHedge, the comments are a veritable gold-mine. In the like above, they don’t disappoint.

With XBI, we have our repeating pattern, link here.

Stay Tuned

Charts by StockCharts, TC2000

Note:  Posts on this site are for education purposes only.  They provide one firm’s insight on the markets.  Not investment advice.  See additional disclaimer here.

The Danger Point®, trade mark: No. 6,505,279

Biotech … The Set-Up

December 23, 2025 By in $SPSIBI, Biotech, David Weis, LABD, LABD-25-22, SPBIO, Spring-to-Up-Thrust, Wyckoff, XBI

Repeating Pattern

The last update on biotech, XBI was here.

Price action went on to post a new high and, in the process, may have completed a repeating pattern set-up:

Spring-to-Up-Thrust, link here.

The indication is subtle.

There’s no doubt we’re at the very edge of the lake as Wyckoff (and Weis) used to call it.

However, this is also the point where the risk (for a short) is least (not advice, not a recommendation).

Stay Tuned

Charts by StockCharts

Note:  Posts on this site are for education purposes only.  They provide one firm’s insight on the markets.  Not investment advice.  See additional disclaimer here.

The Danger Point®, trade mark: No. 6,505,279

Anatomy of a Reversal

December 11, 2025 By in $SPSIBI, Biotech, LABD, LABD-25-20, SPBIO, Up-Thrust, Wyckoff, XBI 1 Comment

Wyckoff Schematic

An excellent schematic tutorial on Wyckoff, can be found here.

Going to the link, scrolling down to ‘Distribution’, we have a schematic that includes the notation “UTAD”.

UTAD, stands for, Upthrust After Distribution.

The accompanying text for the schematic indicates the distribution has already taken place; UTAD, is essentially a ‘last gasp’ to see if there’s any more demand.

A fascinating question would be, ‘Was the heavy volume associated with this update an indication of distribution?’

Does that mean the subsequent blip higher in this update, was essentially UTAD?

Biotech XBI, Hourly

The heavy volume (potential) distribution is noted.

If this is a correct view of XBI, then right now, it’s at The Danger Point®; where risk on a short is least (not advice, not a recommendation).

Stay Tuned

Charts by StockCharts

Note:  Posts on this site are for education purposes only.  They provide one firm’s insight on the markets.  Not investment advice.  See additional disclaimer here.

The Danger Point®, trade mark: No. 6,505,279

Biotech, Hangs at The Wedge

December 10, 2025 By in $SPSIBI, Biotech, Federal Reserve, LABD, LABD-25-20, SPBIO, Up-Thrust, Wyckoff, XBI 1 Comment

Waiting for The Fed?

The last update on biotech presented what was thought to be a reversal condition.

The huge downward thrust with volume, was taken as the clue, some large entity or entities (may) have just exited the market.

Well, it’s been seven trading days since then and it looks like we might be at a pivot point (not advice, not a recommendation).

Biotech XBI, Daily

The reversal (Wyckoff up-thrust) was nearly textbook. The only thing absent, was a lower close for that day.

We’re now hovering at the edge.

The Fed announcement is just over an hour away.

Anything can happen.

MACD (magenta arrow) shows momentum has slowed and lines have crossed to the downside.

Stay Tuned

Charts by StockCharts

Note:  Posts on this site are for education purposes only.  They provide one firm’s insight on the markets.  Not investment advice.  See additional disclaimer here.

The Danger Point®, trade mark: No. 6,505,279

Biotech (reversal) Bookends

December 3, 2025 By in $SPSIBI, Biotech, LABD, LABD-25-19, SPBIO, XBI 2 Comments

Repeating Characteristics

Yesterday, biotech XBI was down on the most volume since May 6th, of this year.

For leveraged inverse fund LABD, it posted the heaviest upside volume, ever.

The chart shows a (potential) repeating characteristic for XBI that occurs at the point of trend change (not advice, not a recommendation).

As always, anything can happen and today’s ‘test’ could fail with XBI continuing higher.

Biotech XBI, Daily Close

The ‘up-thrust’ reversal zone is between support/resistance areas (far left, off chart) at the approximate location of the 50% retrace.

Stay Tuned

Charts by StockCharts

Note:  Posts on this site are for education purposes only.  They provide one firm’s insight on the markets.  Not investment advice.  See additional disclaimer here.

The Danger Point®, trade mark: No. 6,505,279

Biotech Stalls @ 50%

December 2, 2025 By in Biotech, LABD, LABD-25-19, SPBIO, XBI 1 Comment

While All Eyes Focused, on A.I.

At left, the entire biotech (XBI) move from all-time highs to the lows and now, stalled at 50% retrace.

Last week was Fibonacci Week 34, from the ‘Tariff’ lows of early April.

The insert at left is a closer look.

Note how the index has essentially gone straight-up without any testing or (significant) price action congestion.

This behavior suggests a down move may happen just as easily (not advice, not a recommendation).

Stay Tuned

Charts by StockCharts

Note:  Posts on this site are for education purposes only.  They provide one firm’s insight on the markets.  Not investment advice.  See additional disclaimer here.

The Danger Point®, trade mark: No. 6,505,279